Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Glutamic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM8 | O00222 | 2/20 | 0.82 |
| ▸ | GRM6 | O15303 | 2/20 | 0.82 |
| ▸ | GRM7 | Q14831 | 2/20 | 0.82 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.82 |
| ▸ | GRM3 | Q14832 | 2/20 | 0.82 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.82 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.82 |
| ▸ | GSR | P00390 | 1/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.82 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.82 |
| ▸ | GRM5 | P41594 | 1/20 | 0.82 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.82 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.82 |
| ▸ | GRIA3 | P42263 | 1/20 | 0.82 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.82 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.82 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.82 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.82 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.82 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| D-Glutamate SCHEMBL1065173 | 1.00 | GRM8 (0.82) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL27732867 | 0.98 | GRM8 (0.78) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL19717585 | 0.98 | GRM8 (0.78) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL28656083 | 0.98 | GRM8 (0.78) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL28078987 | 0.91 | GRM8 (0.75) | GRM8GRM6GRM7GRM4GRM3 | |
| Glutamic Acid SCHEMBL5704264 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL1330824 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRM3 | |
| Glutamic Acid SCHEMBL1554237 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL17127348 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRM3 | |
| D-Glutamate SCHEMBL1330484 | 0.91 | GRM8 (1.00) | GRM8GRM6GRM7GRM4GRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 232 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024039383-A1 | HOMOGENIZATION METHOD OF INFECTING A MOSQUITO WITH WOLBACHIA | BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY (US) | 2024-02-22 | — | — | WO | claimed |
| US-20190284282-A1 | STABLE PHARMACEUTICAL COMPOSITION | DR. REDDY'S LABORATORIES LIMITED (IN) | 2019-09-19 | — | — | US | claimed |
| EP-3402470-A1 | STABLE PHARMACEUTICAL COMPOSITION | Dr. Reddy's Laboratories Limited (IN) | 2018-11-21 | — | — | EP | claimed |
| CN-108778261-A | Stable pharmaceutical composition | 雷迪博士实验室有限公司 | 2018-11-09 | — | — | CN | claimed |
| WO-2017122121-A1 | STABLE PHARMACEUTICAL COMPOSITION | DR. REDDY'S LABORATORIES LIMITED (IN) | 2017-07-20 | — | — | WO | claimed |
| US-20130137639-A1 | STABLE MIA/CD-RAP FORMULATION | SCIL TECHNOLOGY GMBH (DE) | 2013-05-30 | — | — | US | claimed |
| EP-2563809-A2 | STABLE AQUEOUS MIA/CD-RAP FORMULATIONS | Scil Technology GmbH (DE) | 2013-03-06 | — | — | EP | claimed |
| WO-2011134979-A9 | STABLE AQUEOUS MIA/CD-RAP FORMULATIONS | SCIL TECHNOLOGY GMBH (DE) | 2012-08-16 | — | — | WO | claimed |
| WO-2011134979-A2 | STABLE MIA/CD-RAP FORMULATION | SCIL TECHNOLOGY GMBH (DE) | 2011-11-03 | — | — | WO | claimed |
| US-20110014669-A1 | Production of 1,4 Butanediol in a Microorganism | MICROBIA, INC. | 2011-01-20 | — | — | US | claimed |
| WO-2010085731-A2 | PRODUCTION OF 1,4 BUTANEDIOL IN A MICROORGANISM | MICROBIA, INC. (US) | 2010-07-29 | — | — | WO | claimed |
| EP-0231816-B1 | PHARMACEUTICAL PREPARATIONS FOR THE STABILIZATION OF INTERFERON ALPHA | Dr. Karl Thomae GmbH (DE) | 1991-05-29 | — | — | EP | claimed |
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | AGAIN BIO APS (DK) | 2025-11-27 | — | — | US | disclosed |
| US-12312627-B2 | Microorganisms and methods for production of 4-hydroxybutyrate, 1,4-butanediol and related compounds | GENOMATICA, INC. (US) | 2025-05-27 | — | — | US | disclosed |
| US-20250037787-A1 | CONCENTRATION BOUNDS IN LARGE NETWORKS | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-01-30 | — | — | US | disclosed |
| CN-118792190-A | Method for relieving kidney stones by using probiotics mixed preparation with oxalate and uric acid degradation capability | 兰州大学 | 2024-10-18 | — | — | CN | disclosed |
| EP-1033405-A2 | Sequence-determined DNA fragments and corresponding polypeptides encoded thereby | Ceres Incorporated (US) | 2000-09-06 | — | — | EP | disclosed |
| CN-1199402-A | Method for production of magnesium pyridoxal-5'-phosphate glutamate and intermediate products obtained thereby | STEIGERWALD ARZNEIMITTELWERK (DE) | 1998-11-18 | — | — | CN | disclosed |
| US-5441735-A | Containing Erwinia | CENTRAL GLASS CO., LTD. (JP) | 1995-08-15 | — | — | US | disclosed |
| US-4504515-A | Process for preparing low-fat meat products and in particular sausages with high protein content | HOHENESTER HERMANN (DE) | 1985-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250361531-A1 | MICROORGANISMS AND METHODS FOR PRODUCTION OF 4-HYDROXYBUTYRATE, 1,4-BUTANEDIOL AND RELATED COMPOUNDS | HSD17B10, HSD17B12, HADHB | GRM8 3318/4885GRM6 1974/4885GRM7 2108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.